Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on July 3, 2019, covering events occurring on July 1, 2019. The registrant is a Delaware corporation with its principal executive offices in San Diego, California, and its common stock trades on The NASDAQ Stock Market under the symbol "MEIP".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size by one seat.
- New Director Appointment: Ms. Tamar Howson was appointed to the Board effective July 1, 2019. Her term expires at the December 2021 annual meeting of stockholders.
- Director Retirement: William D. Rueckert notified the Board of his intention not to stand for re-election at the December 2019 annual meeting. The Board has not yet determined whether to nominate a replacement or reduce the Board size.
Guidance, Outlook, and Compensation
Compensatory Arrangements: In connection with her appointment, Ms. Howson received an initial stock option grant to purchase 60,000 shares of common stock:
- 20,000 shares vest over a three-year period.
- 40,000 shares vest in monthly installments over a twelve-month period (consistent with the annual grant for fiscal 2020).
- The exercise price equals the closing price of MEI Pharma common stock on July 1, 2019.
Management Commentary: Ms. Howson was selected for her skills and experience, including over 30 years in the pharmaceutical and biotechnology industries and prior board service at companies such as Organovo Holdings, Inc., Actavis plc, and Lexicon Pharmaceuticals. There are no related party transactions or material plans involving Ms. Howson reportable under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact closing price of MEI Pharma stock on July 1, 2019, to determine the exercise price of Ms. Howson's options.
- Monitor the December 2019 annual meeting of stockholders for the final decision regarding Mr. Rueckert's replacement or Board size reduction.
- Review the attached press release (Exhibit 99.1) for additional details on the Board's strategic rationale.
- Confirm the vesting schedule details in the MEI Pharma, Inc. Amended and Restated 2008 Stock Omnibus Equity Compensation Plan.